SCHEMBL6882028

SCHEMBL6882028

O=C1Nc2ncc(Br)cc2C1=CNc1ccc(O)c2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 3/20 0.46
RAF1 P04049 2/20 0.45
CCNA2 P20248 1/20 0.45
CDK2 P24941 1/20 0.45
CCNA1 P78396 1/20 0.45
FLT3 P36888 1/20 0.36
IDO1 P14902 5/20 0.33
CCNB2 O95067 1/20 0.33
CDK1 P06493 1/20 0.33
HSP90AA1 P07900 1/20 0.33
CCNB1 P14635 1/20 0.33
CCR6 P51684 1/20 0.33
CCNB3 Q8WWL7 1/20 0.33
PLK4 O00444 1/20 0.33
TGM2 P21980 1/20 0.32
EP300 Q09472 1/20 0.32
KAT2B Q92831 1/20 0.32
KAT8 Q9H7Z6 1/20 0.32
GSK3B P49841 1/20 0.32
JAK3 P52333 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6882023 1.00 NTRK1 (0.46) NTRK1RAF1CCNA2CDK2CCNA1
SCHEMBL6872505 0.86 JAK3 (0.41) NTRK1RAF1CCNA2CDK2CCNA1
SCHEMBL6872503 0.86 JAK3 (0.41) NTRK1RAF1CCNA2CDK2CCNA1
SCHEMBL7733049 0.85 CDC25B (0.41) NTRK1RAF1CCNA2CDK2CCNA1
SCHEMBL7733054 0.85 CDC25B (0.41) NTRK1RAF1CCNA2CDK2CCNA1
SCHEMBL6882549 0.82 RAF1 (0.47) NTRK1RAF1FLT3IDO1CDK1
SCHEMBL6882552 0.82 RAF1 (0.47) NTRK1RAF1FLT3IDO1CDK1
SCHEMBL6884634 0.81 KDR (0.36) JAK3
SCHEMBL6882587 0.81 AXL (0.35) NTRK1RAF1CCNA2CDK2CCNA1
SCHEMBL6884628 0.81 KDR (0.36) JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818632-B2 3-(anilinomethylene)oxindoles SMITHKLINE BEECHAM CORPORATION 2004-11-16 US claimed
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia GLENNON KIMBERLEY CAROLINE (US) 2002-07-25 US claimed
EP-1165514-A1 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2002-01-02 EP claimed
WO-2000056710-A1 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2000-09-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia PRKDC, PRKX, BMX NTRK1 1095/4885RAF1 22/4885CCNA2 350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.